Becton Dickinson (BDX) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years. The power of a ...

Investors looking for stocks in the Medical - Dental Supplies sector might want to consider either Becton Dickinson (BDX) or Merit Medical (MMSI) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look. The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate ...

More on the News The company has advised customers to prioritize vial use based on clinical needs, following guidelines from the Infectious Disease Society of America and the World Health Organization. While BD does not anticipate a significant financial impact from this issue, it is fully focused on restoring the supply of blood culture vials to normal levels. Price Performance Image Source: Zacks Investment Research Quest Diagnostics, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term g ...

According to the U.S. Census Bureau, the "U.S. population age 65 and over grew nearly five times faster than the total population over the 100 years from 1920 to 2020." Not only that, the older population reached 55.8 million, representing 16.8% of the nation in 2020. Thanks to the post-World War II baby boom, a mass of humanity entered the frame. Brookdale Senior Living (BKD) Still, prospective investors will require some patience. In the past four quarters, the company incurred a loss per share of 19 cent ...

Core Insights - BD (Becton, Dickinson and Company) is addressing a supply issue related to its BACTEC™ blood culture vials, which is not expected to have a material financial impact on the company [1][2][4] - The company is taking measures to mitigate the impact on patient care by manually allocating blood culture vials and advising customers to prioritize usage based on clinical needs [2][4] Company Overview - BD is a leading global medical technology company with a commitment to improving medical discovery, diagnostics, and care delivery [1][3] - The company employs approximately 70,000 individuals and operates in nearly every country, collaborating with organizations to tackle global health challenges [1] Supply Chain Management - The company is experiencing reduced availability of blood culture vials from its supplier and is implementing various strategies to address this issue, including providing manufacturing expertise to the supplier and modifying production schedules [4] - BD is also collaborating with the U.S. Food and Drug Administration to explore options for mitigating supply delays [4] Communication with Stakeholders - BD has communicated with healthcare providers regarding the supply situation and is actively working to ensure that the majority of global demand is met [2][4] - The company has set up a dedicated website for updates on the BACTEC™ blood culture vials supply [5]

FRANKLIN LAKES, N.J., July 10, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has surpassed its Scope 1 and 2 science-based greenhouse gas (GHG) emissions reduction targets for FY 2023 by 5 percentage points and received approval for near and long-term science-based emissions reduction targets from the Science Based Target initiative (SBTi)[1]. This furthers the company's progress toward its goal to reach net zero GHG emis ...

Ecolab, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 13.3%. ECL's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 1.7%. The tool is intended to help scientists better understand how the molecular machinery within a cell function and how it regulates changes in a cell that can lead to cancer and other diseases. Single-cell studies of various areas of health and disease are currently being conducted by researchers worldwide uti ...

BD Rhapsody™ ATAC-Seq Assay Helps Researchers Understand DNA Regulation and Enable Advancements in Precision Medicine Commercially available globally today, the BD Rhapsody™ ATAC-Seq Assay, BD Rhapsody™ TCR/BCR Next Multiomic Assay and BD Rhapsody™ Intracellular CITE-seq Assay are designed to be used on the BD Rhapsody™ Single-Cell Analysis System – a gentle, microwell-based instrument for conducting single cell multiomic research. Commercially available globally today, the BD Rhapsody™ ATAC-Seq Assay, BD R ...

BD will issue a detailed announcement prior to each quarter's webcast, confirming the date and time of the earnings news release and webcast for that quarter. Third Quarter Fiscal 2024 —Thursday, August 1, 2024 at 8:00 a.m. (ET) Fourth Quarter Fiscal 2024 — Thursday, November 7, 2024 at 8:00 a.m. (ET) Contacts: FRANKLIN LAKES, N.J., June 20, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it plans to host webcasts to disc ...

Becton, Dickinson and Company (BDX) , popularly known as BD, recently announced a definitive agreement to acquire Edwards Lifesciences' (EW) Critical Care product group (Critical Care). The transaction is expected to close before the end of the calendar year 2024, subject to customary regulatory reviews and closing conditions. EW's Critical Care's portfolio includes the gold-standard Swan Ganz pulmonary artery catheter, minimally invasive sensors, non-invasive cuffs, tissue oximetry sensors and monitors. Up ...